Results of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Cancer

被引：19
作者：
Glockzin, Gabriel [1 ]
Ghali, Nabil [1 ]
Lang, Sven A. [1 ]
Schlitt, Hans J. [1 ]
Piso, Pompiliu [1 ]
机构：
[1] Univ Regensburg, Med Ctr, Dept Surg, D-93053 Regensburg, Germany
来源：
JOURNAL OF SURGICAL ONCOLOGY | 2009年 / 100卷 / 04期
关键词：
oncological outcome; survival; complication rate; morbidity; mortality; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; SYSTEMIC CHEMOTHERAPY; SURFACE MALIGNANCIES; MORTALITY ANALYSIS; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; OXALIPLATIN; MORBIDITY;
D O I：
10.1002/jso.21332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide a promising additional treatment option for selected patients with peritoneal carcinomatosis arising from colorectal cancer. Due to the aggressive surgery the concept is associated with a significant morbidity rate. Thus, the operative risk has to be evaluated against the background of the expected improvement of the oncological outcome. J. Surg. Oncol. 2009;100:306-310. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码：306 / 310
页数：5
相关论文
共 43 条
  • [1] Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer
    Culliford, AT
    Brooks, AD
    Sharma, S
    Saltz, LB
    Schwartz, GK
    O'Reilly, EM
    Ilson, DH
    Kemeny, NE
    Kelsen, DP
    Guillem, JG
    Wong, WD
    Cohen, AM
    Paty, PB
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (10) : 787 - 795
  • [2] Limited survival in the treatment of carcinomatosis from rectal cancer
    da Silva, RG
    Cabanas, J
    Sugarbaker, PH
    [J]. DISEASES OF THE COLON & RECTUM, 2005, 48 (12) : 2258 - 2263
  • [3] Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer
    da Silva, Rodrigo Gomes
    Sugarbaker, Paul H.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2006, 203 (06) : 878 - 886
  • [4] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [5] DEDRICK RL, 1985, SEMIN ONCOL, V12, P1
  • [6] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
    Douillard, JY
    Cunningham, D
    Roth, AD
    Navarro, M
    James, RD
    Karasek, P
    Jandik, P
    Iveson, T
    Carmichael, J
    Alakl, M
    Gruia, G
    Awad, L
    Rougier, P
    [J]. LANCET, 2000, 355 (9209) : 1041 - 1047
  • [7] Treatment of peritoneal carcinomatosis from colorectal cancer: Impact of complete cytoreductive surgery and difficulties in conducting randomized trials
    Elias, D
    Delperro, JR
    Sideris, L
    Benhamou, E
    Pocard, M
    Baton, O
    Giovannini, M
    Lasser, P
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (05) : 518 - 521
  • [8] Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin
    Elias, Dominique
    Lefevre, Jeremie H.
    Chevalier, Julie
    Brouquet, Antoine
    Marchal, Frederic
    Classe, Jean-Marc
    Ferron, Gwenael
    Guilloit, Jean-Marc
    Meeus, Pierre
    Goere, Diane
    Bonastre, Julia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 681 - 685
  • [9] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement
    Esquivel, J.
    Sticca, R.
    Sugarbaker, P.
    Levine, E.
    Yan, T. D.
    Alexander, R.
    Baratti, D.
    Bartlett, D.
    Barone, R.
    Barrios, P.
    Bieligk, S.
    Bretcha-Boix, P.
    Chang, C. K.
    Chu, F.
    Chu, Q.
    Daniel, S.
    deBree, E.
    Deraco, M.
    Dominguez-Parra, L.
    Elias, D.
    Flynn, R.
    Foster, J.
    Garofalo, A.
    Gilly, F. N.
    Glehen, O.
    Gomez-Portilla, A.
    Gonzalez-Bayon, L.
    Gonzalez-Moreno, S.
    Goodman, M.
    Gushchin, V.
    Hanna, N.
    Hartmann, J.
    Harrison, L.
    Hoefer, R.
    Kane, J.
    Kecmanovic, D.
    Kelley, S.
    Kuhn, J.
    LaMont, J.
    Lange, J.
    Li, B.
    Loggie, B.
    Mahteme, H.
    Mann, G.
    Martin, R.
    Misih, R. A.
    Moran, B.
    Morris, D.
    Onate-Ocana, L.
    Petrelli, N.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (01) : 128 - 133
  • [10] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
    Falcone, Alfredo
    Ricci, Sergio
    Brunetti, Isa
    Pfanner, Elisabetta
    Allegrini, Giacomo
    Barbara, Cecilia
    Crino, Lucio
    Benedetti, Giovanni
    Evangelista, Walter
    Fanchini, Laura
    Cortesi, Enrico
    Picone, Vincenzo
    Vitello, Stefano
    Chiara, Silvana
    Granetto, Cristina
    Porcile, Gianfranco
    Fioretto, Luisa
    Orlandini, Cinzia
    Andreuccetti, Michele
    Masi, Gianluca
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1670 - 1676
12345